Back to Trial

Oracle Runs

Oracle findings and outcome history for A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (NCT03591510).

Runs
4
Findings
4
Latest Run
Apr 6, 2026, 2:08 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

No public readout or results posted for NCT03591510. Primary completion is Jan 2026; prior abstracts are trial-in-progress or design-only (2019/2023). No sources provide efficacy interpretation, positive/negative framing, or trial-specific outcomes.

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:20 PM
Web Searchclinicaltrials.gov
NCT03591510 | A Global Study of Midostaurin in Combination With Chemotherapy...
Active, not recruiting. Estimated primary completion: 2026-01-19. No results posted.
Web Searchpmc.ncbi.nlm.nih.govAug 8, 2023, 12:00 AM
TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY... (NCT03591510)
Trial in progress. Results: None. Primary objective part 2 is safety; secondary includes response rates and survival. No outcomes reported.
NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
ClinicalTrialsclinicaltrials.govMar 13, 2026, 12:00 AM
Study Details | NCT03591510 | ClinicalTrials.gov
ClinicalTrials.gov lists active not recruiting; primary completion 2026-01-19; hasResults=false on the latest posted update.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No clear trial-specific positive or negative public readout was found. The ClinicalTrials.gov record for NCT03591510 was updated after actual primary completion and explicitly shows "No Results Posted," so there is no posted efficacy interpretation to classify yes or no.

Found Apr 3, 2026, 4:02 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.govMar 13, 2026, 12:00 AM
Study Details | NCT03591510 | ClinicalTrials.gov
ClinicalTrials.gov lists NCT03591510 as Active, not recruiting, with Primary Completion (Actual) 2026-01-19 and the page header/record view states: No Results Posted.
Sponsornovartis.com
RYDAPT prescribing information
The label notes pediatric evidence was limited; for NCT03591510 it references 4 patients and says safety and effectiveness of the pediatric formulation were not established, which is not a clear positive or negative readout for the full trial.
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. ClinicalTrials.gov lists NCT03591510 as active, not recruiting, with primary completion on 2026-01-19 and explicitly says no results posted. Novartis pipeline materials still showed this Phase 2 pediatric AML study’s readout in 2026 with publication TBD, so there is not enough public evidence to call it positive or negative.

Found Apr 1, 2026, 6:37 PMReviewed Apr 1, 2026, 6:46 PM
ClinicalTrialsclinicaltrials.govMar 13, 2026, 12:00 AM
Study Details | NCT03591510 | ClinicalTrials.gov
ClinicalTrials.gov lists NCT03591510 as Active, not recruiting, shows Primary Completion (Actual) 2026-01-19, and states 'No Results Posted' in the record header.
Sponsornovartis.comOct 29, 2024, 12:00 AM
Novartis Q3 2024 Results presentation
Novartis pipeline entry for NCT03591510 shows 'Readout Milestone(s): 2026' and 'Publication TBD' for this Phase 2 pediatric AML study, indicating no disclosed outcome yet.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.